APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Multiple Sclerosis (MS) Drugs

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Multiple Sclerosis (MS) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174014840326 December 2025194 pages

Choose your research edition.

Industry ResearchMultiple Sclerosis (MS) Drugs Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal Multiple Sclerosis (MS) Drugs Industry Growth and Trends Forecast to 2032116 pages · $3,450 USDMarket StructureGlobal Multiple Sclerosis (MS) Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Multiple Sclerosis (MS) Drugs Market Outlook and Growth Opportunities 2026206 pages · $4,250 USDMarket Analysis & ForecastGlobal Multiple Sclerosis (MS) Drugs Market Analysis and Forecast 2026-2032209 pages · $4,950 USD

Market perspective

The global Multiple Sclerosis (MS) Drugs market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Multiple Sclerosis (MS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Multiple Sclerosis (MS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Multiple Sclerosis (MS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Multiple Sclerosis (MS) Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Multiple Sclerosis (MS) Drugs include Eli Lilly, Bayer AG, Innate Immunotherapeutics, Gw Pharmaceuticals, Glaxosmithkline, Genzyme, Genmab, Five Prime Therapeutics and Fast Forward Llc, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Multiple Sclerosis (MS) Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Multiple Sclerosis (MS) Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Multiple Sclerosis (MS) Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Multiple Sclerosis (MS) Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

Multiple Sclerosis (MS) Drugs Segment by Company

Eli Lilly

Bayer AG

Innate Immunotherapeutics

Gw Pharmaceuticals

Glaxosmithkline

Genzyme

Genmab

Five Prime Therapeutics

Fast Forward Llc

Daiichi Sankyo

Cinnagen

Biogen Idec

Bayhill Therapeutics

Artielle Immunotherapeutics

Apitope

Antisense Therapeutics

Multiple Sclerosis (MS) Drugs Segment by Type

Copaxone (Glatiramer Acetate, Copolymer 1)

Firategrast (Sb683699, T-0047)

Gilenya (Fingolimod, Fty720)

Tecfidera (Dimethyl Fumarate)

Aubagio (Teriflunomide)

Siponimod (Baf312)

Novantrone (Mitoxantrone)

Others

Multiple Sclerosis (MS) Drugs Segment by Application

PPMS

PRMS

RRMS

SPMS

Multiple Sclerosis (MS) Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Multiple Sclerosis (MS) Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Multiple Sclerosis (MS) Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Multiple Sclerosis (MS) Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Multiple Sclerosis (MS) Drugs market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Multiple Sclerosis (MS) Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Multiple Sclerosis (MS) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Multiple Sclerosis (MS) Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Multiple Sclerosis (MS) Drugs Industry Trends Table 2. Multiple Sclerosis (MS) Drugs Industry Drivers Table 3. Multiple Sclerosis (MS) Drugs Industry Opportunities and Challenges Table 4. Multiple Sclerosis (MS) Drugs Industry Restraints Table 5. Global Multiple Sclerosis (MS) Drugs Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Multiple Sclerosis (MS) Drugs Sales by Manufacturers (W Units) & (2021-2026) Table 8. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Manufacturers Table 9. Global Multiple Sclerosis (MS) Drugs Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Multiple Sclerosis (MS) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Multiple Sclerosis (MS) Drugs Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Multiple Sclerosis (MS) Drugs Manufacturers, Product Type & Application Table 13. Global Multiple Sclerosis (MS) Drugs Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Multiple Sclerosis (MS) Drugs by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Copaxone (Glatiramer Acetate, Copolymer 1) Table 17. Major Manufacturers of Firategrast (Sb683699, T-0047) Table 18. Major Manufacturers of Gilenya (Fingolimod, Fty720) Table 19. Major Manufacturers of Tecfidera (Dimethyl Fumarate) Table 20. Major Manufacturers of Aubagio (Teriflunomide) Table 21. Major Manufacturers of Siponimod (Baf312) Table 22. Major Manufacturers of Novantrone (Mitoxantrone) Table 23. Major Manufacturers of Others Table 24. Global Multiple Sclerosis (MS) Drugs Sales by Type 2021 VS 2025 VS 2032 (W Units) Table 25. Global Multiple Sclerosis (MS) Drugs Sales by Type (2021-2026) & (W Units) Table 26. Global Multiple Sclerosis (MS) Drugs Sales by Type (2027-2032) & (W Units) Table 27. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2021-2026) Table 28. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2027-2032) Table 29. Global Multiple Sclerosis (MS) Drugs Revenue by Type 2021 VS 2025 VS 2032 (W Units) Table 30. Global Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2026) & (W Units) Table 31. Global Multiple Sclerosis (MS) Drugs Revenue by Type (2027-2032) & (W Units) Table 32. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2021-2026) Table 33. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2027-2032) Table 34. Major Manufacturers of PPMS Table 35. Major Manufacturers of PRMS Table 36. Major Manufacturers of RRMS Table 37. Major Manufacturers of SPMS Table 38. Global Multiple Sclerosis (MS) Drugs Sales by Application 2021 VS 2025 VS 2032 (W Units) Table 39. Global Multiple Sclerosis (MS) Drugs Sales by Application (2021-2026) & (W Units) Table 40. Global Multiple Sclerosis (MS) Drugs Sales by Application (2027-2032) & (W Units) Table 41. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2021-2026) Table 42. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2027-2032) Table 43. Global Multiple Sclerosis (MS) Drugs Revenue by Application 2021 VS 2025 VS 2032 (W Units) Table 44. Global Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2026) & (W Units) Table 45. Global Multiple Sclerosis (MS) Drugs Revenue by Application (2027-2032) & (W Units) Table 46. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2021-2026) Table 47. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2027-2032) Table 48. Global Multiple Sclerosis (MS) Drugs Sales by Region: 2021 VS 2025 VS 2032 (W Units) Table 49. Global Multiple Sclerosis (MS) Drugs Sales by Region (2021-2026) & (W Units) Table 50. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Region (2021-2026) Table 51. Global Multiple Sclerosis (MS) Drugs Sales Forecasted by Region (2027-2032) & (W Units) Table 52. Global Multiple Sclerosis (MS) Drugs Sales Forecasted Market Share by Region (2027-2032) Table 53. North America Multiple Sclerosis (MS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 54. North America Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 55. North America Multiple Sclerosis (MS) Drugs Sales by Country (2027-2032) & (W Units) Table 56. Europe Multiple Sclerosis (MS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 57. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 58. Europe Multiple Sclerosis (MS) Drugs Sales by Country (2027-2032) & (W Units) Table 59. Asia Pacific Multiple Sclerosis (MS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 60. Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 61. Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Country (2027-2032) & (W Units) Table 62. South America, Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (W Units) Table 63. South America, Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2021-2026) & (W Units) Table 64. South America, Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2027-2032) & (W Units) Table 65. Global Multiple Sclerosis (MS) Drugs Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 66. Global Multiple Sclerosis (MS) Drugs Revenue by Region (2021-2026) & (US$ Million) Table 67. Global Multiple Sclerosis (MS) Drugs Revenue by Region (2027-2032) & (US$ Million) Table 68. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2021-2026) Table 69. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2027-2032) Table 70. Eli Lilly Company Information Table 71. Eli Lilly Business Overview Table 72. Eli Lilly Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolio Table 74. Eli Lilly Recent Development Table 75. Bayer AG Company Information Table 76. Bayer AG Business Overview Table 77. Bayer AG Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolio Table 79. Bayer AG Recent Development Table 80. Innate Immunotherapeutics Company Information Table 81. Innate Immunotherapeutics Business Overview Table 82. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 84. Innate Immunotherapeutics Recent Development Table 85. Gw Pharmaceuticals Company Information Table 86. Gw Pharmaceuticals Business Overview Table 87. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolio Table 89. Gw Pharmaceuticals Recent Development Table 90. Glaxosmithkline Company Information Table 91. Glaxosmithkline Business Overview Table 92. Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolio Table 94. Glaxosmithkline Recent Development Table 95. Genzyme Company Information Table 96. Genzyme Business Overview Table 97. Genzyme Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Genzyme Multiple Sclerosis (MS) Drugs Product Portfolio Table 99. Genzyme Recent Development Table 100. Genmab Company Information Table 101. Genmab Business Overview Table 102. Genmab Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Genmab Multiple Sclerosis (MS) Drugs Product Portfolio Table 104. Genmab Recent Development Table 105. Five Prime Therapeutics Company Information Table 106. Five Prime Therapeutics Business Overview Table 107. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 109. Five Prime Therapeutics Recent Development Table 110. Fast Forward Llc Company Information Table 111. Fast Forward Llc Business Overview Table 112. Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolio Table 114. Fast Forward Llc Recent Development Table 115. Daiichi Sankyo Company Information Table 116. Daiichi Sankyo Business Overview Table 117. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolio Table 119. Daiichi Sankyo Recent Development Table 120. Cinnagen Company Information Table 121. Cinnagen Business Overview Table 122. Cinnagen Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolio Table 124. Cinnagen Recent Development Table 125. Biogen Idec Company Information Table 126. Biogen Idec Business Overview Table 127. Biogen Idec Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolio Table 129. Biogen Idec Recent Development Table 130. Bayhill Therapeutics Company Information Table 131. Bayhill Therapeutics Business Overview Table 132. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 133. Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 134. Bayhill Therapeutics Recent Development Table 135. Artielle Immunotherapeutics Company Information Table 136. Artielle Immunotherapeutics Business Overview Table 137. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 138. Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 139. Artielle Immunotherapeutics Recent Development Table 140. Apitope Company Information Table 141. Apitope Business Overview Table 142. Apitope Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 143. Apitope Multiple Sclerosis (MS) Drugs Product Portfolio Table 144. Apitope Recent Development Table 145. Antisense Therapeutics Company Information Table 146. Antisense Therapeutics Business Overview Table 147. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales (W Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 148. Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio Table 149. Antisense Therapeutics Recent Development Table 150. Key Raw Materials Table 151. Raw Materials Key Suppliers Table 152. Multiple Sclerosis (MS) Drugs Distributors List Table 153. Multiple Sclerosis (MS) Drugs Customers List Table 154. Research Programs/Design for This Report Table 155. Authors List of This Report Table 156. Secondary Sources Table 157. Primary Sources List of Figures Figure 1. Multiple Sclerosis (MS) Drugs Product Image Figure 2. Global Multiple Sclerosis (MS) Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Multiple Sclerosis (MS) Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Multiple Sclerosis (MS) Drugs Sales (2021-2032) & (W Units) Figure 5. Global Multiple Sclerosis (MS) Drugs Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Multiple Sclerosis (MS) Drugs Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Copaxone (Glatiramer Acetate, Copolymer 1) Image Figure 9. Firategrast (Sb683699, T-0047) Image Figure 10. Gilenya (Fingolimod, Fty720) Image Figure 11. Tecfidera (Dimethyl Fumarate) Image Figure 12. Aubagio (Teriflunomide) Image Figure 13. Siponimod (Baf312) Image Figure 14. Novantrone (Mitoxantrone) Image Figure 15. Others Image Figure 16. Global Multiple Sclerosis (MS) Drugs Sales by Type (2021 VS 2025 VS 2032) & (W Units) Figure 17. Global Multiple Sclerosis (MS) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 18. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2021-2032) Figure 19. Global Multiple Sclerosis (MS) Drugs Revenue by Type (2021 VS 2025 VS 2032) & (W Units) Figure 20. Global Multiple Sclerosis (MS) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 21. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2021-2032) Figure 22. PPMS Image Figure 23. PRMS Image Figure 24. RRMS Image Figure 25. SPMS Image Figure 26. Global Multiple Sclerosis (MS) Drugs Sales by Application (2021 VS 2025 VS 2032) & (W Units) Figure 27. Global Multiple Sclerosis (MS) Drugs Sales Market Share 2021 VS 2025 VS 2032 Figure 28. Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2021-2032) Figure 29. Global Multiple Sclerosis (MS) Drugs Revenue by Application (2021 VS 2025 VS 2032) & (W Units) Figure 30. Global Multiple Sclerosis (MS) Drugs Revenue Market Share 2021 VS 2025 VS 2032 Figure 31. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2021-2032) Figure 32. North America Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 33. North America Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2021-2032) Figure 34. U.S. Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 35. Canada Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 36. Mexico Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 37. Europe Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 38. Europe Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2021-2032) Figure 39. Germany Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 40. France Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 41. U.K. Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 42. Italy Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 43. Netherlands Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 44. Asia Pacific Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 45. Asia Pacific Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2021-2032) Figure 46. China Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 47. Japan Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 48. South Korea Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 49. Southeast Asia Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 50. India Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 51. Australia Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 52. South America, Middle East and Africa Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 53. South America, Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Market Share by Country (2021-2032) Figure 54. Brazil Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 55. South Africa Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 56. Saudi Arabia Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 57. Turkey Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 58. Argentina Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 59. UAE Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 60. Egypt Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 61. Chile Multiple Sclerosis (MS) Drugs Sales and Growth Rate (2021-2032) & (W Units) Figure 62. Global Multiple Sclerosis (MS) Drugs Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 63. Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 64. North America Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Figure 65. North America Multiple Sclerosis (MS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Europe Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Figure 67. Europe Multiple Sclerosis (MS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Asia-Pacific Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Figure 69. Asia-Pacific Multiple Sclerosis (MS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 70. South America, Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue (2021-2032) & (US$ Million) Figure 71. South America, Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 72. Multiple Sclerosis (MS) Drugs Value Chain Figure 73. Manufacturing Cost Structure Figure 74. Multiple Sclerosis (MS) Drugs Production Mode & Process Figure 75. Direct Comparison with Distribution Share Figure 76. Distributors Profiles Figure 77. Years Considered Figure 78. Research Process Figure 79. Key Executives Interviewed

Scope & coverage.

Types
  • Copaxone (Glatiramer Acetate, Copolymer 1)
  • Firategrast (Sb683699, T-0047)
  • Gilenya (Fingolimod, Fty720)
  • Tecfidera (Dimethyl Fumarate)
  • Aubagio (Teriflunomide)
  • Siponimod (Baf312)
  • Novantrone (Mitoxantrone)
  • Others
Applications
  • PPMS
  • PRMS
  • RRMS
  • SPMS
Companies covered
  • Eli Lilly
  • Bayer AG
  • Innate Immunotherapeutics
  • Gw Pharmaceuticals
  • Glaxosmithkline
  • Genzyme
  • Genmab
  • Five Prime Therapeutics
  • Fast Forward Llc
  • Daiichi Sankyo
  • Cinnagen
  • Biogen Idec
  • Bayhill Therapeutics
  • Artielle Immunotherapeutics
  • Apitope
  • Antisense Therapeutics

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Multiple Sclerosis (MS) Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Multiple Sclerosis (MS) Drugs Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Multiple Sclerosis (MS) Drugs Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Multiple Sclerosis (MS) Drugs Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Multiple Sclerosis (MS) Drugs Market Dynamics
  1. 2.1 Multiple Sclerosis (MS) Drugs Industry Trends
  2. 2.2 Multiple Sclerosis (MS) Drugs Industry Drivers
  3. 2.3 Multiple Sclerosis (MS) Drugs Industry Opportunities and Challenges
  4. 2.4 Multiple Sclerosis (MS) Drugs Industry Restraints
3 Multiple Sclerosis (MS) Drugs Market by Manufacturers
  1. 3.1 Global Multiple Sclerosis (MS) Drugs Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Multiple Sclerosis (MS) Drugs Sales by Manufacturers (2021-2026)
  3. 3.3 Global Multiple Sclerosis (MS) Drugs Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Multiple Sclerosis (MS) Drugs Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Multiple Sclerosis (MS) Drugs Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Multiple Sclerosis (MS) Drugs Manufacturers, Product Type & Application
  7. 3.7 Global Multiple Sclerosis (MS) Drugs Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Multiple Sclerosis (MS) Drugs Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Multiple Sclerosis (MS) Drugs Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Multiple Sclerosis (MS) Drugs Tier 1, Tier 2, and Tier 3
4 Multiple Sclerosis (MS) Drugs Market by Type
  1. 4.1 Multiple Sclerosis (MS) Drugs Type Introduction
  2. 4.1.1 Copaxone (Glatiramer Acetate, Copolymer 1)
  3. 4.1.2 Firategrast (Sb683699, T-0047)
  4. 4.1.3 Gilenya (Fingolimod, Fty720)
  5. 4.1.4 Tecfidera (Dimethyl Fumarate)
  6. 4.1.5 Aubagio (Teriflunomide)
  7. 4.1.6 Siponimod (Baf312)
  8. 4.1.7 Novantrone (Mitoxantrone)
  9. 4.1.8 Others
  10. 4.2 Global Multiple Sclerosis (MS) Drugs Sales by Type
  11. 4.2.1 Global Multiple Sclerosis (MS) Drugs Sales by Type (2021 VS 2025 VS 2032)
  12. 4.2.2 Global Multiple Sclerosis (MS) Drugs Sales by Type (2021-2032)
  13. 4.2.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Type (2021-2032)
  14. 4.3 Global Multiple Sclerosis (MS) Drugs Revenue by Type
  15. 4.3.1 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2021 VS 2025 VS 2032)
  16. 4.3.2 Global Multiple Sclerosis (MS) Drugs Revenue by Type (2021-2032)
  17. 4.3.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Type (2021-2032)
5 Multiple Sclerosis (MS) Drugs Market by Application
  1. 5.1 Multiple Sclerosis (MS) Drugs Application Introduction
  2. 5.1.1 PPMS
  3. 5.1.2 PRMS
  4. 5.1.3 RRMS
  5. 5.1.4 SPMS
  6. 5.2 Global Multiple Sclerosis (MS) Drugs Sales by Application
  7. 5.2.1 Global Multiple Sclerosis (MS) Drugs Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Multiple Sclerosis (MS) Drugs Sales by Application (2021-2032)
  9. 5.2.3 Global Multiple Sclerosis (MS) Drugs Sales Market Share by Application (2021-2032)
  10. 5.3 Global Multiple Sclerosis (MS) Drugs Revenue by Application
  11. 5.3.1 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Multiple Sclerosis (MS) Drugs Revenue by Application (2021-2032)
  13. 5.3.3 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Application (2021-2032)
6 Global Multiple Sclerosis (MS) Drugs Sales by Region
  1. 6.1 Global Multiple Sclerosis (MS) Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Multiple Sclerosis (MS) Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global Multiple Sclerosis (MS) Drugs Sales by Region (2021-2026)
  4. 6.2.2 Global Multiple Sclerosis (MS) Drugs Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Multiple Sclerosis (MS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Multiple Sclerosis (MS) Drugs Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Multiple Sclerosis (MS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Multiple Sclerosis (MS) Drugs Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Multiple Sclerosis (MS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Multiple Sclerosis (MS) Drugs Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Multiple Sclerosis (MS) Drugs Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Multiple Sclerosis (MS) Drugs Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Multiple Sclerosis (MS) Drugs Revenue by Region
  1. 7.1 Global Multiple Sclerosis (MS) Drugs Revenue by Region
  2. 7.1.1 Global Multiple Sclerosis (MS) Drugs Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Multiple Sclerosis (MS) Drugs Revenue by Region (2021-2026)
  4. 7.1.3 Global Multiple Sclerosis (MS) Drugs Revenue by Region (2027-2032)
  5. 7.1.4 Global Multiple Sclerosis (MS) Drugs Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Multiple Sclerosis (MS) Drugs Revenue (2021-2032)
  8. 7.2.2 North America Multiple Sclerosis (MS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Multiple Sclerosis (MS) Drugs Revenue (2021-2032)
  11. 7.3.2 Europe Multiple Sclerosis (MS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Multiple Sclerosis (MS) Drugs Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Multiple Sclerosis (MS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Multiple Sclerosis (MS) Drugs Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly
  2. 8.1.1 Eli Lilly Company Information
  3. 8.1.2 Eli Lilly Business Overview
  4. 8.1.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly Multiple Sclerosis (MS) Drugs Product Portfolio
  6. 8.1.5 Eli Lilly Recent Developments
  7. 8.2 Bayer AG
  8. 8.2.1 Bayer AG Company Information
  9. 8.2.2 Bayer AG Business Overview
  10. 8.2.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer AG Multiple Sclerosis (MS) Drugs Product Portfolio
  12. 8.2.5 Bayer AG Recent Developments
  13. 8.3 Innate Immunotherapeutics
  14. 8.3.1 Innate Immunotherapeutics Company Information
  15. 8.3.2 Innate Immunotherapeutics Business Overview
  16. 8.3.3 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Innate Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  18. 8.3.5 Innate Immunotherapeutics Recent Developments
  19. 8.4 Gw Pharmaceuticals
  20. 8.4.1 Gw Pharmaceuticals Company Information
  21. 8.4.2 Gw Pharmaceuticals Business Overview
  22. 8.4.3 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Gw Pharmaceuticals Multiple Sclerosis (MS) Drugs Product Portfolio
  24. 8.4.5 Gw Pharmaceuticals Recent Developments
  25. 8.5 Glaxosmithkline
  26. 8.5.1 Glaxosmithkline Company Information
  27. 8.5.2 Glaxosmithkline Business Overview
  28. 8.5.3 Glaxosmithkline Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Glaxosmithkline Multiple Sclerosis (MS) Drugs Product Portfolio
  30. 8.5.5 Glaxosmithkline Recent Developments
  31. 8.6 Genzyme
  32. 8.6.1 Genzyme Company Information
  33. 8.6.2 Genzyme Business Overview
  34. 8.6.3 Genzyme Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Genzyme Multiple Sclerosis (MS) Drugs Product Portfolio
  36. 8.6.5 Genzyme Recent Developments
  37. 8.7 Genmab
  38. 8.7.1 Genmab Company Information
  39. 8.7.2 Genmab Business Overview
  40. 8.7.3 Genmab Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Genmab Multiple Sclerosis (MS) Drugs Product Portfolio
  42. 8.7.5 Genmab Recent Developments
  43. 8.8 Five Prime Therapeutics
  44. 8.8.1 Five Prime Therapeutics Company Information
  45. 8.8.2 Five Prime Therapeutics Business Overview
  46. 8.8.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  48. 8.8.5 Five Prime Therapeutics Recent Developments
  49. 8.9 Fast Forward Llc
  50. 8.9.1 Fast Forward Llc Company Information
  51. 8.9.2 Fast Forward Llc Business Overview
  52. 8.9.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Fast Forward Llc Multiple Sclerosis (MS) Drugs Product Portfolio
  54. 8.9.5 Fast Forward Llc Recent Developments
  55. 8.10 Daiichi Sankyo
  56. 8.10.1 Daiichi Sankyo Company Information
  57. 8.10.2 Daiichi Sankyo Business Overview
  58. 8.10.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Product Portfolio
  60. 8.10.5 Daiichi Sankyo Recent Developments
  61. 8.11 Cinnagen
  62. 8.11.1 Cinnagen Company Information
  63. 8.11.2 Cinnagen Business Overview
  64. 8.11.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Cinnagen Multiple Sclerosis (MS) Drugs Product Portfolio
  66. 8.11.5 Cinnagen Recent Developments
  67. 8.12 Biogen Idec
  68. 8.12.1 Biogen Idec Company Information
  69. 8.12.2 Biogen Idec Business Overview
  70. 8.12.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Biogen Idec Multiple Sclerosis (MS) Drugs Product Portfolio
  72. 8.12.5 Biogen Idec Recent Developments
  73. 8.13 Bayhill Therapeutics
  74. 8.13.1 Bayhill Therapeutics Company Information
  75. 8.13.2 Bayhill Therapeutics Business Overview
  76. 8.13.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  78. 8.13.5 Bayhill Therapeutics Recent Developments
  79. 8.14 Artielle Immunotherapeutics
  80. 8.14.1 Artielle Immunotherapeutics Company Information
  81. 8.14.2 Artielle Immunotherapeutics Business Overview
  82. 8.14.3 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Artielle Immunotherapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  84. 8.14.5 Artielle Immunotherapeutics Recent Developments
  85. 8.15 Apitope
  86. 8.15.1 Apitope Company Information
  87. 8.15.2 Apitope Business Overview
  88. 8.15.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Apitope Multiple Sclerosis (MS) Drugs Product Portfolio
  90. 8.15.5 Apitope Recent Developments
  91. 8.16 Antisense Therapeutics
  92. 8.16.1 Antisense Therapeutics Company Information
  93. 8.16.2 Antisense Therapeutics Business Overview
  94. 8.16.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Price, Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Product Portfolio
  96. 8.16.5 Antisense Therapeutics Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Multiple Sclerosis (MS) Drugs Value Chain Analysis
  2. 9.1.1 Multiple Sclerosis (MS) Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Multiple Sclerosis (MS) Drugs Production Mode & Process
  6. 9.2 Multiple Sclerosis (MS) Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Multiple Sclerosis (MS) Drugs Distributors
  9. 9.2.3 Multiple Sclerosis (MS) Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst